Tower Research Capital LLC TRC Boosts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA)

Tower Research Capital LLC TRC raised its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 65.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,623 shares of the company’s stock after buying an additional 1,042 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Cabaletta Bio were worth $60,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Amalgamated Bank boosted its holdings in shares of Cabaletta Bio by 24.7% in the third quarter. Amalgamated Bank now owns 4,648 shares of the company’s stock valued at $71,000 after acquiring an additional 922 shares in the last quarter. Macroview Investment Management LLC acquired a new stake in Cabaletta Bio in the fourth quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Cabaletta Bio by 29.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,798 shares of the company’s stock valued at $256,000 after purchasing an additional 3,798 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Cabaletta Bio during the 3rd quarter worth approximately $63,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Cabaletta Bio during the 4th quarter worth approximately $113,000.

Analyst Ratings Changes

Several research firms have recently commented on CABA. Citigroup raised their price target on Cabaletta Bio from $26.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Wells Fargo & Company raised their target price on Cabaletta Bio from $34.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. HC Wainwright upped their price target on shares of Cabaletta Bio from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $50.00 price target on shares of Cabaletta Bio in a report on Friday, April 5th. Finally, Jefferies Financial Group started coverage on shares of Cabaletta Bio in a report on Monday, February 5th. They set a “buy” rating and a $36.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $34.33.

Cabaletta Bio Stock Down 4.8 %

Shares of Cabaletta Bio stock traded down $0.53 on Monday, hitting $10.48. The company’s stock had a trading volume of 5,070,481 shares, compared to its average volume of 1,028,918. The company has a market capitalization of $490.57 million, a P/E ratio of -6.35 and a beta of 2.42. Cabaletta Bio, Inc. has a 52-week low of $9.02 and a 52-week high of $26.35. The firm has a fifty day moving average price of $18.24 and a 200-day moving average price of $18.83.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Thursday, March 21st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). As a group, analysts expect that Cabaletta Bio, Inc. will post -1.82 earnings per share for the current year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.